In Celexir’s specialized category, Melittin is positioned strictly as a research-oriented peptide for targeted inflammation and exploratory oncology/immune applications. Catalog guidance frames it as investigational—appropriate where clinicians are evaluating mechanisms rather than prescribing patient-ready therapy.
Mechanistically, melittin is the principal peptide in bee venom and a classic pore-forming cytolytic peptide: it inserts into lipid bilayers and permeabilizes membranes; contemporary biophysics refines the model as nucleation-driven, transient/large pores rather than simple equilibrium aggregation. At signaling levels, low-dose contexts show NF-κB inhibition and downstream reductions in pro-inflammatory mediators, aligning with its anti-inflammatory research profile.
Translational interest centers on delivery strategies that blunt off-target lysis—liposomes, niosomes, and other nanoparticles—to explore anticancer and anti-inflammatory potential while improving tolerability. Reviews and preclinical studies report tumor-directed effects and gene-level shifts when melittin is encapsulated or targeted, but these remain preclinical/early-stage signals rather than definitive clinical benefit.
Clinical and regulatory caution: free melittin is hemolytic and cytotoxic, and bee-venom components can provoke allergic reactions and anaphylaxis; authoritative reviews flag these risks as the key barrier to systemic use. While some regional sources describe limited pain-swelling indications linked to bee-venom therapy, a U.S. UNII entry emphasizes that identifier status does not imply FDA approval. In Celexir’s catalog, Melittin is research-use only, supplied as a lyophilized vial with documentation for controlled laboratory evaluation.